Haima Therapeutics is proud to support our co-founder and CTO, Anirban Sen Gupta, as he presents at the Gordon Research Conference: Cell Biology of Megakaryocytes and Platelets this week! He will be sharing exciting updates on #SynthoPlate and its future advancements alongside his graduate student, Norman Luc. In addition to presenting, Dr. Sen Gupta is leading the session "Platelets at Work," highlighting the critical roles platelets play beyond hemostasis. We’re also excited to see Haima #SAB member, Wolfgang Bergmeier, chairing the session "Platelets in the Immune Crossfire," exploring the intersection of platelet biology and immune function. This conference brings together the world’s leading experts in platelet science, and we’re thrilled to contribute to these important discussions. Looking forward to the insights and collaborations that will come from this week! #biotech #hemostasis #innovation #platelets #GRC https://lnkd.in/gumq4mUb
关于我们
Haima Therapeutics is a pre-clinical stage biotechnology company focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. We have developed a novel, nanoparticle-based synthetic hemostatic technology, called SynthoPlate, that can staunch hemorrhagic bleeding by binding to the site of injury and amplifying your body’s natural clotting mechanisms. Haima Therapeutics and Case Western Reserve University entered into an option to license agreement in April of 2018. Haima Therapeutics is located at the BioEnterprise incubator centrally located in the University Circle area near Case Western Reserve University, University Hospitals, and the Cleveland Clinic.
- 网站
-
https://www.haimatherapeutics.com/
Haima Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 总部
- Cleveland，Ohio
- 类型
- 私人持股
- 创立
- 2016
地点
-
主要
获取路线
11000 Cedar Ave
US，Ohio，Cleveland
Haima Therapeutics员工
-
Stephen Flaim, Ph.D., FACC, FAHA
-
Anirban Sen Gupta
Wallace R. Persons Endowed Professor of Engineering, Biomedical Engineering, Case Western Reserve University. FAIMBE, FBSE, NAI Senior Member…
-
Michael Bruckman
CEO at Haima Therapeutics
-
Ujjal Didar Singh Sekhon, PhD
Senior Scientist @ Haima Therapeutics | Nanomedicine | Lipid Nanoparticles | Hemostasis | Neurodegenerative Diseases | Driving cutting-edge research…
动态
-
Nature has engineered platelets to be the ultimate first responders for bleeding control. At Haima Therapeutics, we are harnessing this intricate biology to develop #SynthoPlate, a synthetic platelet-inspired technology designed to support hemostasis in critical clinical settings such as after traumatic injury, during major surgery, incidents of PPH, and for those with bleeding disorders. Our partnership with Dr.?Anirban Sen Gupta’s lab at Case Western Reserve University has been instrumental in translating groundbreaking research into a promising therapeutic platform. We look forward to exciting advancements as we continue to push the boundaries of bleeding management! #SyntheticPlatelets #BleedingControl #BiotechInnovation #HaimaTherapeutics
Wallace R. Persons Endowed Professor of Engineering, Biomedical Engineering, Case Western Reserve University. FAIMBE, FBSE, NAI Senior Member. Scientist and Entrepreneur.
Platelets are like a #SwissArmyKnife. They have multiple elegant complementary ‘tools’ (mechanisms) that individually and collectively allow them to surveil the blood vessel interface for signs of injury, and jump into action as soon as they sense vascular damage to rapidly form a clot that prevents bleeding (Hemostasis). Over the past decade, our lab at Case Western Reserve University Department of Biomedical Engineering has successfully developed nanoparticle-based systems that can modularly mimic these mechanisms, leading to several generations of #SyntheticPlatelets. Via partnership with Haima Therapeutics we are advancing these patented technologies for bleeding management in various clinical settings, with #SynthoPlate as the lead product.
-
-
Exciting Collaboration with Cleveland Clinic on SynthoPlate Research! Haima Therapeutics is thrilled to announce the successful initiation of our collaboration with Cleveland Clinic on our #NIH National Heart, Lung, and Blood Institute #SBIR Phase 2 project! This critical study will evaluate #SynthoPlate's ability to restore hemostatic function in patients with severe thrombocytopenia, a life-threatening condition caused by dangerously low platelet levels. This final phase follows our successful demonstration of efficacy and safety in a rabbit model of chemotherapy-induced thrombocytopenia, bringing us one step closer to a transformative solution for patients in need. We are honored to work alongside Dr. Paolo Caimi, a leading hematologist/oncologist at the Cleveland Clinic, whose expertise will be invaluable in advancing this research. A huge thank you to our exceptional team at Haima—Kristin Aldridge, Emily Gahagan, Ujjal Didar Singh Sekhon, PhD, Christa L. Pawlowski, PhD, Emma Quill, Baylee Traylor and Michael Bruckman (PI)—for their dedication and leadership in pushing this project forward. Together, we are committed to developing cutting-edge therapies that can make a meaningful impact in hematology and patient care! #biotech #hematology #platelets #innovation #startup #NIHFunding
-
?? Advancing Trauma Care: The Role of Platelets and Synthetic Blood Products Platelets play a critical role in stopping bleeding, a process that can be the difference between life and death in trauma settings. Traditional donor platelets, though life-saving, have limitations—most notably a shelf life of just 5 days. Enter #SynthoPlate, a platelet-mimicking hemostatic agent therapeutic developed by Haima Therapeutics and licensed from Case Western Reserve University (Anirban Sen Gupta). SynthoPlate, in addition to being effective and safe as a solo treatment, boasts an extended stability of over a year, representing a monumental leap in addressing the logistical challenges of platelet storage and availability. We are proud to collaborate with KaloCyte, Inc., developers of #ErythroMer, as part of DARPA’s #FSHARP program—a partnership aimed at creating innovative solutions for synthetic blood substitutes. Together, we’re advancing technologies that tackle trauma, the leading cause of life years lost and the primary cause of death for individuals under 44, as highlighted by a member of Haima's SAB, Dr. Phil Spinella's, and Dr. Holcomb’s profound statements in the excellent article in The New Yorker. https://lnkd.in/eTDKCP4e #HaimaTherapeutics #TraumaCare #SyntheticPlatelets #DARPAFSHARP #LifeSavingTech Allan Doctor Elaine Haynes John Holcomb Jean-Paul Chretien Christa L. Pawlowski, PhD